Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05702034 | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE | PHASE3 | ACTIVE NOT_RECRUITING | 12,532 | — | — | Feb 15, 2023 | Dec 9, 2026 | Jun 5, 2026 | 880 | United States, Argentina +45 |
Time to first occurrence of ischemic stroke will be reported.
| Arm | Type | Description |
|---|---|---|
| Milvexian | EXPERIMENTAL | Participants after an acute ischemic stroke or high-risk transient ischemic attack (TIA) who are receiving antiplatelet therapy standard-of-care (SAPT \[single antiplatelet therapy\] or DAPT \[dual antiplatelet therapy\]) will receive milvexian 25 milligrams (mg), orally, twice daily. |
| Placebo | PLACEBO_COMPARATOR | Participants after an acute ischemic stroke or high-risk TIA who are receiving antiplatelet therapy standard-of-care (SAPT or DAPT) will receive placebo orally twice daily. |
| Name | Type | Description |
|---|---|---|
| Milvexian | DRUG | Milvexian will be administered orally. |
| Placebo | DRUG | Placebo will be administered orally |
Inclusion Criteria: * Ischemic Stroke: a neurological deficit attributable to an acute brain infarction and national institute of health stroke score scale (NIHSS) score less than or equal to (\<=) 7 and at least 1 of the following: persistent signs or symptoms of the ischemic event at the time of ...